Medis’ relentless commitment to providing the best-in-class physiology solution for almost a decade has led to this landmark milestone
Leiden, NL, October 1, 2024 – Medis’ Quantitative Flow Ratio (QFR®) has been awarded with a Class I recommendation in 3 distinct categories of the 2024 ESC guidelines for the management of patients suffering from Chronic Coronary Syndrome (CCS). This recognition recommends QFR® as a physiology measurement technique next to, and at par with, the traditional wire-based methods. The guidelines also differentiate Medis QFR® from other Angiography-based FFR techniques, which have been called out with a lower IIb/C recommendation, in only one of the 3 categories.
“We are proud and honored to have received these recommendations from the 2024 ESC guidelines”, said Hans Reiber, CSO at Medis Medical Imaging. “This is testament to the hard work and countless hours spent by the entire team for more than a decade. None of this would have been possible without the strong support and guidance of our clinical partners and collaborators. We can’t thank them enough for the strong collaboration over the years and look ahead to many more successful years that we spend developing technology for the patients.”
The first category, for which 2024 ESC guidelines awarded Medis QFR® with a Class IB recommendation, is assessing epicardial artery stenosis. Medis QFR® is based on 3D QCA and flow velocity. Unlike other angiography-based vessel FFR methods, which have a Class IIb/C recommendation, studies have shown that QFR-guided interventions result in fewer myocardial infarctions and ischaemia-driven revascularizations. The guidelines are sending a clear message that physiology is proven to be better than standard visual interpretation of angiograms. Medis QFR® is fast, proven, and available for both prospective and retrospective data analysis. It’s a physiology platform rather than a single measurement device.
The second category is revascularization in patients with Chronic Coronary Syndrome. Here, Medis QFR® was awarded a Class IA recommendation to guide lesion selection for intervention in patients with multivessel disease. QFR enables multi-vessel and multi-lesion investigations using only angiograms which helps physicians avoid introducing a pressure wire into the different coronary vessels of interest, reducing the associated risks and consumable expenses. Additionally, it has been further proven in multiple trials that a post-PCI QFR>0.90 results in better long-term outcome for the patient.
The third and final category is the management of Chronic Coronary Syndrome (CCS) patients with chronic heart failure. Here, Medis QFR® was awarded a Class IC recommendation in heart failure patients with left ventricular ejection fraction (LVEF) >35% and suspected CCS with very high (>85%) pre-test likelihood of obstructive coronary artery disease.
Finally, the 2024 ESC guidelines emphasized that current concepts in understanding and managing CCS have broadened to embrace structural and functional abnormalities in both the macro- and microvascular compartments of the coronary tree that may lead to transient myocardial ischemia. It was of particular interest for Medis Medical Imaging to note the comment on the angiography-derived index of coronary microcirculatory resistance (angio-IMR) that allows microcirculation assessment without using intracoronary wires which is precisely what QFR-IMR® offers.
“I am incredibly proud to see our QFR technology recognized in the latest ESC guidelines” said Maya Barley, CEO at Medis Medical Imaging. “This inclusion is a testament to the rigorous research, clinical validation, and innovation that Medis brings to the cardiovascular imaging space in tandem with our clinical partners. Our team remains committed to delivering cutting-edge solutions that enhance patient care and provide physicians with the most advanced tools to make critical decisions.”
About Medis Medical Imaging
For over 35 years, Medis Medical Imaging has been providing high-quality quantitative analysis solutions for cardiovascular imaging to the medical community. Our heritage and core values are based on this strong purpose of contributing to a healthier society by providing the right tools to clinicians worldwide. Medis’ software is internationally appreciated due to its ease of use and its clinical outcome for the patients. At Medis Medical Imaging, quality is key, all our products are developed and validated extensively to guarantee the highest quality, without compromise. We continuously focus on the creation of clinically relevant innovative software solutions in the cardiovascular imaging domain.
